Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotechnology company Cadence Pharmaceuticals
With that in mind, let's take a closer look at Cadence's business and see what CAPS investors are saying about the stock right now.
|Headquarters (founded)||San Diego (2004)|
|Market Cap||$367.0 million|
|Trailing-12-Month Revenue||$24.4 million|
|Management||Co-Founder/CEO Theodore Schroeder
CFO William LaRue
|Return on Equity (average, past 3 years)||(76.4%)|
|Cash/Debt||$108.6 million / $28.8 million|
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 37% of the 98 members who have rated Cadence believe the stock will underperform the S&P 500 going forward.
Cadence has gapped down on earnings the last three quarters and I don't see that as likely to change on August 2. Ofirmev revenues have been increasing moderately behind a furious marketing drive but are still a long way from matching SGA expenses and quarterly burn. With the share price up 50% from recent lows as the summer tide lifts the biopharma sector, look to Cadence to be at the forefront of the wave back downward.
If you want market-thumping returns, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future. Cadence, with its one-star rating, may not fit the bill for your portfolio.
Fortunately, we've found another stock we are incredibly excited about -- excited enough to dub it "The Motley Fool's Top Stock for 2012." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.